The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF

A. D'Addio, A. Curti, N. Worel, K. Douglas, M. R. Motta, S. Rizzi, E. Dan, S. Taioli, V. Giudice, H. Agis, G. Kopetzky, R. Soutar, B. Casadei, M. Baccarani, R. M. Lemoli

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

We report 13 multiple myeloma (MM) or lymphoma patients who were failing PBSC mobilization after disease-specific chemotherapy and granulocyte-CSF (G-CSF), and received plerixafor to successfully collect PBSCs. Patients were considered poor mobilizers when the concentration of PB CD34 cells was always lower than 10 cells/L, during the recovery phase after chemotherapy and/or were predicted to have inadequate PBSC collection to proceed to autologous transplantation. Plerixafor (0.24 mg/kg) was administered subcutaneously for up to three consecutive days, while continuing G-CSF, 10-11 h before the planned leukapheresis. Plerixafor administration was safe and no significant adverse events were recorded. We observed a 4.7 median fold-increase in the number of circulating CD34 cells after plerixafor as compared with baseline CD34 cell concentration (from a median of 6.2 (range 1-12) to 21.5 (range 9-88) cells/L). All patients collected 2 × 10 6 CD34 cells/kg in 1-3 leukaphereses. In all, 5/13 patients have already undergone autograft with plerixafor-mobilized PBSCs, showing a rapid and durable hematological recovery. Our results suggest that the pre-emptive addition of plerixafor to G-CSF after chemotherapy is safe and may allow the rescue of lymphoma and MM patients, who need autologous transplantation but are failing PBSC mobilization.

Original languageEnglish
Pages (from-to)356-363
Number of pages8
JournalBone Marrow Transplantation
Volume46
Issue number3
DOIs
Publication statusPublished - Mar 2011

Fingerprint

Multiple Myeloma
Granulocytes
Lymphoma
Drug Therapy
Leukapheresis
Autologous Transplantation
Autografts
JM 3100

Keywords

  • autologous stem cell transplantation
  • PBSC mobilization
  • plerixafor
  • poor mobilizers

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. / D'Addio, A.; Curti, A.; Worel, N.; Douglas, K.; Motta, M. R.; Rizzi, S.; Dan, E.; Taioli, S.; Giudice, V.; Agis, H.; Kopetzky, G.; Soutar, R.; Casadei, B.; Baccarani, M.; Lemoli, R. M.

In: Bone Marrow Transplantation, Vol. 46, No. 3, 03.2011, p. 356-363.

Research output: Contribution to journalArticle

D'Addio, A, Curti, A, Worel, N, Douglas, K, Motta, MR, Rizzi, S, Dan, E, Taioli, S, Giudice, V, Agis, H, Kopetzky, G, Soutar, R, Casadei, B, Baccarani, M & Lemoli, RM 2011, 'The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF', Bone Marrow Transplantation, vol. 46, no. 3, pp. 356-363. https://doi.org/10.1038/bmt.2010.128
D'Addio, A. ; Curti, A. ; Worel, N. ; Douglas, K. ; Motta, M. R. ; Rizzi, S. ; Dan, E. ; Taioli, S. ; Giudice, V. ; Agis, H. ; Kopetzky, G. ; Soutar, R. ; Casadei, B. ; Baccarani, M. ; Lemoli, R. M. / The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. In: Bone Marrow Transplantation. 2011 ; Vol. 46, No. 3. pp. 356-363.
@article{d0296cb461db4b9a81920c88d7f2c1f4,
title = "The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF",
abstract = "We report 13 multiple myeloma (MM) or lymphoma patients who were failing PBSC mobilization after disease-specific chemotherapy and granulocyte-CSF (G-CSF), and received plerixafor to successfully collect PBSCs. Patients were considered poor mobilizers when the concentration of PB CD34 cells was always lower than 10 cells/L, during the recovery phase after chemotherapy and/or were predicted to have inadequate PBSC collection to proceed to autologous transplantation. Plerixafor (0.24 mg/kg) was administered subcutaneously for up to three consecutive days, while continuing G-CSF, 10-11 h before the planned leukapheresis. Plerixafor administration was safe and no significant adverse events were recorded. We observed a 4.7 median fold-increase in the number of circulating CD34 cells after plerixafor as compared with baseline CD34 cell concentration (from a median of 6.2 (range 1-12) to 21.5 (range 9-88) cells/L). All patients collected 2 × 10 6 CD34 cells/kg in 1-3 leukaphereses. In all, 5/13 patients have already undergone autograft with plerixafor-mobilized PBSCs, showing a rapid and durable hematological recovery. Our results suggest that the pre-emptive addition of plerixafor to G-CSF after chemotherapy is safe and may allow the rescue of lymphoma and MM patients, who need autologous transplantation but are failing PBSC mobilization.",
keywords = "autologous stem cell transplantation, PBSC mobilization, plerixafor, poor mobilizers",
author = "A. D'Addio and A. Curti and N. Worel and K. Douglas and Motta, {M. R.} and S. Rizzi and E. Dan and S. Taioli and V. Giudice and H. Agis and G. Kopetzky and R. Soutar and B. Casadei and M. Baccarani and Lemoli, {R. M.}",
year = "2011",
month = "3",
doi = "10.1038/bmt.2010.128",
language = "English",
volume = "46",
pages = "356--363",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF

AU - D'Addio, A.

AU - Curti, A.

AU - Worel, N.

AU - Douglas, K.

AU - Motta, M. R.

AU - Rizzi, S.

AU - Dan, E.

AU - Taioli, S.

AU - Giudice, V.

AU - Agis, H.

AU - Kopetzky, G.

AU - Soutar, R.

AU - Casadei, B.

AU - Baccarani, M.

AU - Lemoli, R. M.

PY - 2011/3

Y1 - 2011/3

N2 - We report 13 multiple myeloma (MM) or lymphoma patients who were failing PBSC mobilization after disease-specific chemotherapy and granulocyte-CSF (G-CSF), and received plerixafor to successfully collect PBSCs. Patients were considered poor mobilizers when the concentration of PB CD34 cells was always lower than 10 cells/L, during the recovery phase after chemotherapy and/or were predicted to have inadequate PBSC collection to proceed to autologous transplantation. Plerixafor (0.24 mg/kg) was administered subcutaneously for up to three consecutive days, while continuing G-CSF, 10-11 h before the planned leukapheresis. Plerixafor administration was safe and no significant adverse events were recorded. We observed a 4.7 median fold-increase in the number of circulating CD34 cells after plerixafor as compared with baseline CD34 cell concentration (from a median of 6.2 (range 1-12) to 21.5 (range 9-88) cells/L). All patients collected 2 × 10 6 CD34 cells/kg in 1-3 leukaphereses. In all, 5/13 patients have already undergone autograft with plerixafor-mobilized PBSCs, showing a rapid and durable hematological recovery. Our results suggest that the pre-emptive addition of plerixafor to G-CSF after chemotherapy is safe and may allow the rescue of lymphoma and MM patients, who need autologous transplantation but are failing PBSC mobilization.

AB - We report 13 multiple myeloma (MM) or lymphoma patients who were failing PBSC mobilization after disease-specific chemotherapy and granulocyte-CSF (G-CSF), and received plerixafor to successfully collect PBSCs. Patients were considered poor mobilizers when the concentration of PB CD34 cells was always lower than 10 cells/L, during the recovery phase after chemotherapy and/or were predicted to have inadequate PBSC collection to proceed to autologous transplantation. Plerixafor (0.24 mg/kg) was administered subcutaneously for up to three consecutive days, while continuing G-CSF, 10-11 h before the planned leukapheresis. Plerixafor administration was safe and no significant adverse events were recorded. We observed a 4.7 median fold-increase in the number of circulating CD34 cells after plerixafor as compared with baseline CD34 cell concentration (from a median of 6.2 (range 1-12) to 21.5 (range 9-88) cells/L). All patients collected 2 × 10 6 CD34 cells/kg in 1-3 leukaphereses. In all, 5/13 patients have already undergone autograft with plerixafor-mobilized PBSCs, showing a rapid and durable hematological recovery. Our results suggest that the pre-emptive addition of plerixafor to G-CSF after chemotherapy is safe and may allow the rescue of lymphoma and MM patients, who need autologous transplantation but are failing PBSC mobilization.

KW - autologous stem cell transplantation

KW - PBSC mobilization

KW - plerixafor

KW - poor mobilizers

UR - http://www.scopus.com/inward/record.url?scp=79952535006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952535006&partnerID=8YFLogxK

U2 - 10.1038/bmt.2010.128

DO - 10.1038/bmt.2010.128

M3 - Article

VL - 46

SP - 356

EP - 363

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 3

ER -